罗欣药业
(002793)
| 流通市值：51.47亿 | | | 总市值：51.55亿 |
| 流通股本：10.86亿 | | | 总股本：10.88亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,147,454,455.61 | 582,726,187.11 | 2,273,457,651.02 | 1,723,415,167.25 |
| 营业总成本 | 1,070,756,842.95 | 559,455,929.53 | 2,515,661,813.36 | 1,736,037,629.45 |
| 其他经营收益 | | | | |
| 营业利润 | 78,565,537.15 | 41,914,119.7 | -300,250,506.45 | 56,070,711.81 |
| 利润总额 | 73,490,228.32 | 42,696,080.54 | -290,871,968.58 | 51,318,934.12 |
| 净利润 | 53,233,137.12 | 28,995,465.62 | -284,526,170.23 | 33,559,116.79 |
| 每股收益 | | | | |
| 其他综合收益 | -4,409,190.25 | -1,558,099.61 | 23,563,654.64 | 27,997,669.16 |
| 综合收益总额 | 48,823,946.87 | 27,437,366.01 | -260,962,515.59 | 61,556,785.95 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,852,715,315.65 | 1,755,627,666.59 | 1,928,943,457.17 | 1,685,728,983.02 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,761,993,655.43 | 1,813,498,977.37 | 1,796,349,021.25 | 2,304,417,683.59 |
| 资产总计 | 3,614,708,971.08 | 3,569,126,643.96 | 3,725,292,478.42 | 3,990,146,666.61 |
| 流动负债: | | | | |
| 流动负债合计 | 2,341,397,149.11 | 2,307,870,427.18 | 2,298,054,698.34 | 2,069,972,451.21 |
| 非流动负债: | | | | |
| 非流动负债合计 | 70,475,272.06 | 86,063,282.62 | 191,546,180.22 | 390,083,917.53 |
| 负债合计 | 2,411,872,421.17 | 2,393,933,709.8 | 2,489,600,878.56 | 2,460,056,368.74 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,126,280,236.68 | 1,099,803,135.44 | 1,164,035,433.35 | 1,452,480,831.45 |
| 股东权益合计 | 1,202,836,549.91 | 1,175,192,934.16 | 1,235,691,599.86 | 1,530,090,297.87 |
| 负债和股东权益合计 | 3,614,708,971.08 | 3,569,126,643.96 | 3,725,292,478.42 | 3,990,146,666.61 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,520,078,831.08 | 727,553,538.4 | 2,381,378,767.28 | 2,024,224,167.33 |
| 经营活动现金流出小计 | 1,209,871,280.07 | 585,845,559.27 | 2,128,313,089.01 | 1,744,108,372.61 |
| 经营活动产生的现金流量净额 | 310,207,551.01 | 141,707,979.13 | 253,065,678.27 | 280,115,794.72 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 46,420,270.57 | 38,385,737.5 | 175,805,230.9 | 74,500,112.58 |
| 投资活动现金流出小计 | 18,112,447.84 | 8,626,370.34 | 51,746,516.55 | 31,487,691.31 |
| 投资活动产生的现金流量净额 | 28,307,822.73 | 29,759,367.16 | 124,058,714.35 | 43,012,421.27 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 585,826,720 | 324,170,620 | 1,306,293,069.3 | 1,209,141,592.96 |
| 筹资活动现金流出小计 | 597,111,016 | 294,387,956.34 | 1,641,312,475.75 | 1,502,131,084.19 |
| 筹资活动产生的现金流量净额 | -11,284,296 | 29,782,663.66 | -335,019,406.45 | -292,989,491.23 |
| 汇率变动对现金及现金等价物的影响 | -5,024,304.35 | -1,523,243.08 | -1,229,131.41 | -1,832,533.11 |
| 现金及现金等价物净增加额 | 322,206,773.39 | 199,726,766.87 | 40,875,854.76 | 28,306,191.65 |
| 期末现金及现金等价物余额 | 652,472,043.57 | 528,974,636.95 | 330,265,270.18 | 317,695,607.07 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 322,206,773.39 | - | 40,875,854.76 | - |